Rothblatt Martine A's Form 4 filing
United Therapeutics Corp (UTHR) · filed Oct 6, 2025
- Accession no.
- 0001106578-25-000016
- Filed
- Oct 6, 2025
- Trade date
- Oct 3-6, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.58M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rothblatt Martine ACIK 0001106578 | Director, Officer (Chairperson & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 3, 2025 | Common Stock | MOption exerciseAcquired | +4,000 | $120.26 | +$481,040 | 4,130 | Direct | |
| Oct 3, 2025 | Common Stock | SSaleDisposed | −1,000 | $443.63 | −$443,630 | 3,130 | Direct | |
| Oct 3, 2025 | Common Stock | SSaleDisposed | −1,629 | $445.61F2 | −$725,898.69 | 1,501 | Direct | |
| Oct 3, 2025 | Common Stock | SSaleDisposed | −1,371 | $448.81F3 | −$615,318.51 | 130 | Direct | |
| Oct 6, 2025 | Common Stock | MOption exerciseAcquired | +4,000 | $120.26 | +$481,040 | 4,130 | Direct | |
| Oct 6, 2025 | Common Stock | SSaleDisposed | −1,000 | $445.24 | −$445,240 | 3,130 | Direct | |
| Oct 6, 2025 | Common Stock | SSaleDisposed | −3,000 | $451.18F4 | −$1,353,540 | 130 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 3, 2025 | Common Stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 214,000 | Direct | |
| Oct 6, 2025 | Common Stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 210,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $445.385 to $445.755. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $448.48 to $449.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $450.555 to $451.485. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.